Good morning :)
$
₹
Adagene Inc

Adagene Inc

ADAG

NASDAQ
Asset Logo

Adagene Inc

ADAG

NASDAQ
$2.0216.09% (-0.38)
$
₹
$2.0216.09% (-0.38)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $157.8M the stock is ranked 4394

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.71
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.37
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-220.77%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 6 analysts reports

Buy
6 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+311.13%

Earnings Growth

—

Rev. Growth

-74.45%

See Detailed Forecast

Company Profile

Company Profile

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
49.14
49.14
1Y Return
36.01%
36.01%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.64
28.64
1Y Return
50.65%
50.65%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
42.33%
42.33%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.59
35.59
1Y Return
30.09%
30.09%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.51
21.51
1Y Return
40.33%
40.33%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 311.13% growth, versus a trailing 3-year CAGR of 21.31%.

2026
Current$2.41Baseline
Analyst Target - 1 year
Target$9.91+311.13%

All values in $

202220232024202520262027$3.62$6.04$8.47Target+311.13%
2026
Current$2.41Baseline
Analyst Target - 1 year
Target$9.91+311.13%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -74.45% growth, versus a trailing 3-year CAGR of -6.19%.

2025
Current$7.67Baseline
Forecast for Dec 2026
High$3-60.89%
Average$1.96-74.45%
Low$1.6-79.14%

All values in $ Million

20212022202320242025202610.179.2918.110.107.67Low-79.14%Average-74.45%High-60.89%
2025
Current$7.67Baseline
Forecast for Dec 2026
High$3-60.89%
Average$1.96-74.45%
Low$1.6-79.14%

All values in $ Million

Financials

Financials

Income

Balance Sheet

Cash Flow

-13.5
7.6
-4.1
1.6
-16.4
Q2 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ3 2023Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q2 2025Q4 2025Q1 2026Q2 2026
Total Revenue0.400.40---0.10--7.691.62
Net Income-7.41-7.41-8.50-8.50-8.50-24.91-13.51--4.14-16.41
Net Profit Margin-1818.89%-1818.89%----24144.65%---53.86%-1011.09%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Adagene Inc -1.71-
AbbVie Inc49.1450.450.58
Amgen Inc28.6421.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare ADAG with any stock or ETF
Compare ADAG with any stock or ETF
Comparing from
ADAG
ABBV
AMGN
Loading...

Frequently asked questions

  1. Adagene Inc (ADAG) share price today is $2.02 as of November 6, 2026 at 2:29 AM IST. The stock touched a day high of $2.41 and a day low of $2.00.

  2. Adagene Inc stock trades on NASDAQ under the ticker symbol ADAG.

  3. Adagene Inc's market capitalization is $157.78M as of November 6, 2026 at 2:29 AM IST.

  4. Adagene Inc's price-to-earnings (P/E) ratio is N/A as of November 5, 2026.

  5. Adagene Inc's price-to-book (P/B) ratio is 1.71 as of November 5, 2026.

  6. Yes, You can buy Adagene Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Adagene Inc shares in three steps: 1. Search Adagene Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Adagene Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Adagene Inc (ADAG) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 4.9455 shares at the current price of $2.02.

Loading...